



January 6, 2009

Marketing Approval for Brevibloc® (esmolol) Injection

Phebra is pleased to announce that it has achieved marketing approval for Brevibloc in Australia.

Brevibloc has marketing approval for the treatment of supraventricular tachycardia and non-compensatory sinus tachycardia. It is used for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting beta blocker is desirable.

“We are pleased to reach this significant milestone with Brevibloc”, said Dr Mal Eutick, CEO of Phebra, “we understand that anaesthetists believe that Brevibloc provides precise, flexible control of heart rate and blood pressure in the perioperative setting from intubation through to recovery and is the short acting beta-blocker of choice”.

Phebra will be marketing Brevibloc 100mg in 10mL injection to Australian hospitals and supply is now available.

Phebra is an Australian based speciality pharmaceutical company.

At Phebra, we create critical medicines that save and improve lives.